Item 1.02. Termination of a Material Definitive Agreement.
As a result of the mutual termination of the Lantibiotic ECC, the Company will cease pre-clinical development of its product candidate OG716 and other compounds covered by the Lantibiotic ECC, all licenses provided pursuant to the Lantibiotic ECC between the parties were terminated and there are no continuing obligations between the parties, except as to confidentiality. The Company made no payments to EGI in connection with the mutual termination. Each party retained all right and title to their own respective intellectual property.
The Company will focus on its continuing independent research and development efforts relative to lantibiotics in order to identify new compounds to pursue.
© Edgar Online, source